The short answer
- Osteoarthritis is usually not rated - many applicants get preferred pricing.
- Rheumatoid arthritis is priced on severity, not on having it.
- Your medication is read as a severity marker, especially long-term steroids.
- Organ involvement is what moves lupus from a rating to a hard case.
Where you stand
Osteoarthritis is rarely rated at all
The most common form of arthritis is a wear condition, not a systemic disease. On its own it usually has no effect on your rate, and plenty of applicants with it still qualify for preferred pricing.
Check my options →What decides your rate
Underwriters separate mechanical joint wear from autoimmune disease, and price them completely differently:
- Which condition - osteoarthritis, rheumatoid arthritis, psoriatic arthritis and lupus are not read the same way
- Disease activity - flare frequency, and whether it is in remission
- Medication - biologics and long-term oral steroids signal a more active disease
- Organ involvement - lung, kidney or cardiac involvement is the difference between a rating and a decline
- Mobility and independence - what you can still do day to day
What each situation typically means
| Condition and activity | Realistic route |
|---|---|
| Osteoarthritis | Standard, often preferred |
| Rheumatoid arthritis, mild, well controlled | Standard to mild rating |
| Rheumatoid arthritis on biologics | Table rating |
| Psoriatic arthritis, controlled | Mild to moderate rating |
| Lupus, no organ involvement | Table rating |
| Lupus with kidney involvement | Substandard or simplified issue |
Your medication list is the application
For autoimmune arthritis, the current medication list and your rheumatologist notes tell an underwriter more than any answer you write on a form. Long-term oral steroids in particular are read as a marker of a disease that has not settled - so if you have been tapered off them, make sure that is documented.
Why osteoarthritis is treated so differently
Osteoarthritis is joint wear. It hurts, it limits people, and it has almost nothing to do with mortality - which is the only thing a life underwriter is pricing. That disconnect surprises applicants who expect a painful condition to cost them.
The exception is indirect: if arthritis has severely limited your mobility, or if you are managing it with long-term opioids, those are underwritten in their own right.
Lupus and organ involvement
Lupus is the hardest of the group, and the deciding question is whether it has affected an organ. Skin and joint lupus that has stayed there is commonly insurable at a rating. Kidney involvement changes the picture substantially and often moves an application toward simplified issue.
Time matters here too. A long stretch without a flare, on stable medication, with normal kidney function, is a materially better application than a recent diagnosis still being brought under control.
The order to apply
- Confirm the exact diagnosis - people often say arthritis for very different conditions
- Gather your current medication list, including any steroid history
- Get recent bloodwork, and kidney function if you have lupus
- Have an agent pre-screen informally before any formal application
Common questions
Does arthritis affect life insurance rates?+
Osteoarthritis usually does not. Rheumatoid arthritis and other autoimmune forms can, but they are priced on how active the disease is, what medication controls it and whether any organs are involved, rather than on the diagnosis alone.
Can you get life insurance with rheumatoid arthritis?+
Yes. Mild, well controlled rheumatoid arthritis is often approved at standard to a mild rating. More active disease, particularly if it needs biologics or long-term steroids, tends to draw a table rating.
Can you get life insurance with lupus?+
Usually yes, at a rating. Lupus without organ involvement is insurable with several carriers. Kidney involvement is the finding that narrows the options most, and may move you toward simplified or guaranteed issue.
Do biologics affect my application?+
They are noted, but not as a penalty in themselves. Underwriters read medication as evidence of how severe the underlying disease is. A biologic that has produced stable remission can support a better outcome than an uncontrolled disease on lighter treatment.